Piper Sandler Cuts AXSM Price Target to $238
Key Points
- Piper Sandler reduced its price target on Axsome Therapeutics to $238, down from $258, while maintaining an Overweight rating.
- Piper Sandler's $238 price target implies 64.09% upside from Axsome Therapeutics, Inc.'s ($AXSM) current $145.04 share price.
- As of October 26, 2026, Axsome shares recently traded at $145.04, which is about equal to the event close on October 23.
- Analysts have a consensus recommendation of Strong Buy for Axsome, with a mean price target of $280.33.
Get Axsome Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $AXSM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Axsome Therapeutics, Inc. alert may contain errors. Disclosures
On October 26, 2026, Piper Sandler lowered its price target on Axsome Therapeutics, Inc. (AXSM) to $238 from $258, while maintaining an Overweight rating. This change reflects Piper Sandler's ongoing assessment of the company's market position and future prospects.
The new target suggests a significant gap from the current share price. Axsome's shares closed at $145.04 on October 23, and they were trading at the same level as of October 26. This price is about 39.1% below the new target set by Piper Sandler, indicating that analysts see considerable upside potential.
AXSM
Axsome Therapeutics, Inc.
Piper Sandler vs. the S&P 500
Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Axsome Therapeutics
Deep Track Capital, Lp trimmed its position in Axsome, selling 399,937 shares, leaving it with 700,000 shares valued at approximately $101.5 million. In contrast, Two Sigma Investments, LP increased its stake by 346,698 shares, bringing its total to 669,478 shares worth about $97.1 million.
Axsome Therapeutics, Inc. Stock Down 7.1%
Axsome shares recently traded around $145.04, which is about equal to the closing price on October 23. The stock is currently below its 50-day moving average by about 24.4% and is also down around 27.5% from its 200-day moving average. Compared to its 52-week high of $260.19, the stock is down about 44.3%, but it remains 17.4% above its 52-week low of $123.50.
$AXSM price target
Axsome Therapeutics, Inc. daily closes and this analyst's $238 target. Not advice.
Recent Earnings
Axsome Therapeutics reported trailing twelve-month revenue of $776.6 million, with a year-over-year revenue growth of 45.5%. However, the company has a negative net margin of 24.7% and a return on equity of -245.1%. Its next earnings report is scheduled for November 2, 2026.
Insider Buying and Selling at Axsome Therapeutics, Inc.
Several insiders have sold shares recently. CEO Herriot Tabuteau sold 49,664 shares at an average price of $240.25 on July 1, 2026, totaling about $11.9 million. Another sale by Tabuteau occurred on August 6, where he sold 49,664 shares, valued at approximately $10.5 million. Additionally, Director Roger A. Jeffs sold 572 shares on June 11, 2026, valued at about $141,656.
Analysts Set New Price Targets
On October 26, 2026, Piper Sandler maintained its Overweight rating while lowering its price target to $238 from $258. Other firms have also adjusted their targets recently, with Truist Securities maintaining a Buy rating and a target of $285, and Deutsche Bank keeping a Buy rating with a target of $267.
About Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical company based in New York, NY. It focuses on developing and delivering therapies aimed at treating central nervous system disorders. The recent changes in analyst ratings and price targets reflect market expectations for the company's performance in this sector.
Bottom Line
Investors will be looking to the upcoming earnings report on November 2, 2026, for further insights into Axsome's financial health. With Piper Sandler's lowered target and the stock trading significantly below it, market watchers will be keen to see how the company performs moving forward.
Related Filing Alerts
Source: Piper Sandler's rating change on $AXSM (Oct 26, 2026). Written by software, not financial advice. How we make alerts